Navigation Links
Oppenheimer's 24th Annual Healthcare Conference Provides Investor Access To Emerging And Established Companies
Date:12/13/2013

NEW YORK, Dec. 13, 2013 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings Inc., is  pleased to announce the completion of its 24th Annual Healthcare Conference, which took place on December 10 – 11, 2013, in New York.   More than 130 public and private companies, representing  all major sectors of the healthcare industry including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers participated in this two-day program.  The conference attracted more than 700 attendees.

The Oppenheimer Healthcare Conference consisted of a mix of formal company presentations and one-on-one meetings.  

The keynote speaker Ted Kennedy, Jr., President & Co-Founder, The Marwood Group, provided insights into the latest developments in Washington , D.C. and discussed the regulatory environment as well as the headwinds and tailwinds across many sectors of the healthcare industry.  

"This is Oppenheimer's 24th consecutive year of producing this conference, and it demonstrates our long-standing commitment to the healthcare industry. We are pleased to be able to continue to offer this conference for investors to meet with emerging and established healthcare companies as they evaluate the opportunities in the sector over the next 12-18 months," said Erica Moffett, Managing Director and Associate Director of Research.

Panels included "How Emerging Biopharma Companies Successfully Execute Their First Commercial Launch," and "China Healthcare Holds Opportunities for Global Investors and Healthcare Companies: How to Capture Them?"  Other panels looked at the growing use of big data in healthcare and the evolving healthcare model which included CEOs of two of the leading hospital systems in the U.S. discussing  the significant payment and care delivery changes ahead.

In the current environment of healthcare reform, increased regulation and rising costs, the conference offered investors a unique opportunity to meet with CEOs and CFOs of healthcare companies and learn first hand what issues and trends will drive the sector in 2014 and beyond in the  U.S., Europe and China.  

"The Oppenheimer Healthcare Conference has been an excellent forum to highlight our plans for launching OTREXUP following the NDA approval in October," said Paul Wotton, President and CEO of Antares Pharma.

Oppenheimer provides research coverage of more than 110 companies in the healthcare sector and is an active underwriter of healthcare stocks.

Oppenheimer & Co. Inc., a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Oppenheimer & Co. Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
4. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
5. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
6. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
7. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
8. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
9. Henry Schein To Present At The Deutsche Bank 37th Annual Health Care Conference
10. Stereotaxis Epoch™ Solutions Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting
11. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):